Viral Inactivation Market Set to Reach US$ 4.68 Billion by 2031 at... Anesthesia drugs play a critical role in modern healthcare by enabling pain-free surgical and diagnostic procedures. These medications are widely used across hospitals, ambulatory surgical centers, an...

Viral Inactivation Market Set to Reach US$ 4.68 Billion by 2031 at 8.5% CAGR

Source: ruh.org.tr/blogs/32335/...

#ViralInactivation #Biopharmaceuticals #Bioprocessing

Edgewise Therapeutics Issues Inducement Grants Under Nasdaq Regulations Edgewise Therapeutics announced the grant of stock options to new employees to incentivize their joining, in line with Nasdaq regulations.

Edgewise Therapeutics Issues Inducement Grants Under Nasdaq Regulations #USA #biopharmaceuticals #Boulder #muscle_diseases #Edgewise_Therapeutics

Avid Organics to Launch the World’s First Commercial-Scale Bio-Based Glycolic Acid, AviGa™ Bio HP70, at in-cosmetics® Paris renewable-carbon.eu/news/?p=175159 #biochemicals #biofeedstocks #biopharmaceuticals #cosmetics #personalcare #skincare #RenewableCarbon

Harbour BioMed Unveils 2025 Financial Results and Future Plans for Global Growth Discover how Harbour BioMed achieved remarkable growth in 2025, supported by strategic collaborations and innovative therapeutics driving its future.

Harbour BioMed Unveils 2025 Financial Results and Future Plans for Global Growth #China #Shanghai #biopharmaceuticals #Harbour_BioMed #antibody_therapeutics

Tigermed Reports Impressive Growth in 2025 Annual Results with Record Revenue Hangzhou Tigermed Consulting Co. Ltd. announces substantial revenue growth for 2025, signaling a strong future for its global biopharmaceutical services.

Tigermed Reports Impressive Growth in 2025 Annual Results with Record Revenue #China #biopharmaceuticals #Hangzhou #Clinical_Trials #Tigermed

Tigermed Reports Impressive Annual Results for 2025 Showing Strong Growth in Clinical Research Tigermed Consulting announces its annual results for 2025, showcasing a remarkable growth in revenue and significant advancements in R&D solutions.

Tigermed Reports Impressive Annual Results for 2025 Showing Strong Growth in Clinical Research #China #biopharmaceuticals #Hangzhou #Clinical_Research #Tigermed

Lario Therapeutics awarded $2.4m to advance calcium channel platform - PharmaTimes Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD

#precisionmedicines #LarioTherapeutics #MJFF #Wellcome #Parkinsonsdisease #posttraumaticstressdisorder #PTSD #neuronalcalciumchanneldrugdiscoveryplatform #biopharmaceuticals #CaV13linkedParkinsonsdisease #TargetstoTherapiesinitiative #CaV23 #CACNA1Egene
zurl.co/HaJec

Peritia Welcomes Michael A. Griffith as New Chief Executive Officer to Drive Growth Peritia has announced the appointment of Michael A. Griffith as CEO. His expertise in biopharmaceuticals is set to enhance the company's growth and innovation strategies.

Peritia Welcomes Michael A. Griffith as New Chief Executive Officer to Drive Growth #USA #biopharmaceuticals #Morrisville #Peritia #Michael_Griffith

UCB Chooses Rowen for $2 Billion Biopharmaceutical Manufacturing Site in Georgia Global biopharmaceutical leader UCB has chosen Rowen, Georgia, for a significant $2 billion manufacturing campus, marking a new era in life sciences innovation.

UCB Chooses Rowen for $2 Billion Biopharmaceutical Manufacturing Site in Georgia #United_States #biopharmaceuticals #UCB #Gwinnett_County #Rowen

Kelun-Biotech's 2025 Annual Results Showcase Successful Product Launches and Promising Future Kelun-Biotech's recent annual results reveal a successful year with multiple product launches and a strong development pipeline, solidifying its market position.

Kelun-Biotech's 2025 Annual Results Showcase Successful Product Launches and Promising Future #China #biopharmaceuticals #Chengdu #Kelun-Biotech #ADCs

IDEAYA Biosciences to Showcase Cutting-Edge Cancer Research at AACR 2026 Annual Meeting IDEAYA Biosciences reveals three important presentations at AACR 2026, showcasing novel therapies targeting various cancers through innovative scientific approaches.

IDEAYA Biosciences to Showcase Cutting-Edge Cancer Research at AACR 2026 Annual Meeting #United_States #San_Diego #biopharmaceuticals #Cancer_Research #IDEAYA_Biosciences

Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D. as CTO to Enhance Technical Operations Neurocrine Biosciences has named Andrew Ratz, Ph.D., as Chief Technical Operations Officer, underscoring the company's commitment to expanding its biopharmaceutical capabilities.

Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D. as CTO to Enhance Technical Operations #USA #San_Diego #biopharmaceuticals #Neurocrine_Biosciences #Andrew_Ratz

BioDlink Earns Title of 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Awards BioDlink has been awarded 'Emerging CDMO of the Year,' recognizing its innovation in biologics and ADC development through advanced technology and quality systems.

BioDlink Earns Title of 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Awards #China #Suzhou #biopharmaceuticals #ADC_Development #BioDlink

RBL LLC Welcomes Chris Duke as New Operating Partner to Boost Biotech Ventures RBL LLC has appointed Chris Duke as operating partner, bringing rich experience in biopharmaceuticals to enhance biotech venture creation, focusing on breakthrough medical technologies.

RBL LLC Welcomes Chris Duke as New Operating Partner to Boost Biotech Ventures #United_States #biopharmaceuticals #Houston #RBL_LLC #Chris_Duke

Investigation Launched by Ademi Firm on Day One Biopharmaceuticals' Deal for Fair Shareholder Pricing Ademi LLP is conducting an investigation into Day One Biopharmaceuticals, Inc. regarding potential breaches of fiduciary duties linked to a recent transaction with Servier.

Investigation Launched by Ademi Firm on Day One Biopharmaceuticals' Deal for Fair Shareholder Pricing #USA #biopharmaceuticals #Milwaukee #Ademi_Firm #DAY_ONE

Contract development and manufacturing organisation FUJIFILM Biotechnologies has expanded its site in Teesside with a £400 million investment.

healthcaretoday.com/article/fuji...

#Healthcare #Biotech #Biopharmaceuticals #Expansion

Edgewise Therapeutics Announces Inducement Stock Option Grants for New Employees Edgewise Therapeutics has granted stock options to new employees, as part of their strategy to attract talent and comply with Nasdaq listing rules.

Edgewise Therapeutics Announces Inducement Stock Option Grants for New Employees #United_States #biopharmaceuticals #Boulder #Edgewise_Therapeutics #EWTX

Enliven Therapeutics Set to Showcase Innovations at Upcoming Health Care Conference Enliven Therapeutics, a promising biopharmaceutical firm, announces its participation in the TD Cowen 46th Annual Health Care Conference, focusing on innovative therapeutic solutions.

Enliven Therapeutics Set to Showcase Innovations at Upcoming Health Care Conference #USA #biopharmaceuticals #Boulder #Enliven_Therapeutics #Health_Care_Conference

Advancements in Pharmaceutical and Biotech Analysis Techniques for Drug Discovery Explore the latest developments in biopharmaceutical analysis, emphasizing advanced techniques for structural analysis and characterization crucial for drug discovery.

Advancements in Pharmaceutical and Biotech Analysis Techniques for Drug Discovery #Japan #biopharmaceuticals #Tokyo #Drug_Analysis #Analytical_Techniques

Welcome Blake Arnold, CFA, to Kenai as Chief Business Officer!

Blake brings nearly two decades of experience in #biopharmaceuticals and life sciences, and will lead Kenai’s business development, financing, strategic partnerships, and corporate development initiatives.

Read more: bit.ly/4qY73c6

PTC Therapeutics Announces Participation in Notable Investor Conferences This March PTC Therapeutics, Inc. will feature key executives at major healthcare conferences in March 2026, highlighting their advancements in rare disorders.

PTC Therapeutics Announces Participation in Notable Investor Conferences This March #USA #biopharmaceuticals #PTC_Therapeutics #Warren #Health_Conference

The Growing Market for Preparative and Process Chromatography: Trends and Projections Until 2031 The Preparative and Process Chromatography market is set to rise to $21.50 billion by 2031, driven by advancements in biopharmaceuticals and purification processes.

The Growing Market for Preparative and Process Chromatography: Trends and Projections Until 2031 #USA #biopharmaceuticals #Delray_Beach #Market_Trends #chromatography

Hydrophobic Interaction Chromatography Market Expected to Hit $952.9 Million by 2033 The hydrophobic interaction chromatography market is projected to reach $952.9 million globally by 2033, driven by rising demand for biologics and monoclonal antibodies.

Hydrophobic Interaction Chromatography Market Expected to Hit $952.9 Million by 2033 #United_States #biopharmaceuticals #Wilmington #Monoclonal_Antibodies #Hydrophobic_Interaction_Chromatography

Insmed to Showcase Innovative Biopharmaceutical Therapies at Upcoming Investor Conferences in 2026 Insmed Incorporated announces its participation in two major investor conferences in March 2026, showcasing its commitment to patient-focused biopharmaceutical advancements.

Insmed to Showcase Innovative Biopharmaceutical Therapies at Upcoming Investor Conferences in 2026 #United_States #biopharmaceuticals #investor_events #Bridgewater #Insmed

AsymBio Rolling Out Advanced Integrated Technology Platforms for Biopharmaceutical Development AsymBio has announced the launch of its comprehensive technology platforms designed to cover all stages of biopharmaceutical development, enhancing innovation efficiency.

AsymBio Rolling Out Advanced Integrated Technology Platforms for Biopharmaceutical Development #China #Shanghai #biopharmaceuticals #AsymBio #Asymchem_Group

Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026 Join Decoy Therapeutics on February 10, 2026, for an enlightening session at Webull's Corporate Connect Webinar Series. Explore their advancements in antiviral therapeutics!

Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026 #USA #biopharmaceuticals #Cambridge #Webull #Decoy_Therapeutics

Global Standardization of Veeva Link Key People Adopted by Leading BioPharmaceutical Companies Veeva Systems announced that 13 out of the top 20 biopharmaceutical companies are streamlining their data systems with Veeva Link Key People to enhance global healthcare interactions.

Global Standardization of Veeva Link Key People Adopted by Leading BioPharmaceutical Companies #USA #biopharmaceuticals #Veeva_Systems #Barcelona #Link_Key_People

Millrock Technology Welcomes Tom Hochuli as New CEO to Lead Growth Tom Hochuli joins Millrock Technology as CEO, bringing over three decades of experience in life sciences and biopharmaceuticals to drive innovation and growth.

Millrock Technology Welcomes Tom Hochuli as New CEO to Lead Growth #USA #biopharmaceuticals #Millrock_Technology #Kingston,_NY #Tom_Hochuli

Ipsen announces new data on Dysport in neurological disease - PharmaTimes Dysport reduces muscle contractions by blocking the transmission of nerve impulses

#neurology #Ipsen #Dysport #abobotulinumtoxinA #neurologicaldisease #clinicaldata #stroke #neurologicaldisorders #EPITOMEstudy #poststrokespasticity #PSS #strokepatients #realworlddata #strokesurvivors #botulinumtoxintypeA #BoNTA #PSStreatment #BoNTAinjectable #biopharmaceuticals
zurl.co/nLqKq

WuXi Biologics' CEO Dr. Chris Chen Unveils Growth Strategies at JPM 2026 Dr. Chris Chen showcased WuXi Biologics' accomplishments and future ambitions at JPM 2026, speaking on integrated projects and strategic growth initiatives.

WuXi Biologics' CEO Dr. Chris Chen Unveils Growth Strategies at JPM 2026 #None #biopharmaceuticals #San_Francisco #WuXi_Biologics #Dr._Chris_Chen